MedTrace Logo

Transdermally Delivered Human Insulin Product

NCT03544996 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2018-06-06

No results posted yet for this study

Summary

An Early Feasibility Study of a device formulation to deliver human insulin across intact skin

Conditions

  • Hypoinsulinemia

Interventions

COMBINATION_PRODUCT

TD Insulin

Human Insulin USP formulated in a solution capable of transdermal delivery.

Sponsors & Collaborators

  • Transdermal Delivery Solutions Corp

    lead INDUSTRY

Principal Investigators

  • William D Kirsh, D.O. · Sentry Data Systems

Eligibility

Min Age
60 Years
Max Age
61 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-09
Primary Completion
2018-02-04
Completion
2018-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03544996 on ClinicalTrials.gov